HCG (Human Chorionic Gonadotropin)

HCG (Human Chorionic Gonadotropin) is a glycoprotein hormone that mimics luteinizing hormone (LH) activity at the Leydig cells. It is widely used in men's health clinics to maintain testicular function and fertility during testosterone replacement therapy (TRT), and has a long history in weight loss protocols. FDA regulatory changes have significantly impacted compounding availability.

Category
Hormonal Support
Demand
High
Route
Subcutaneous injection, intramuscular injection
FDA status
Reclassified as biologic (March 2020); compounding eligibility restricted. Verify current 503A/503B status with pharmacy partner
Also known as
Human Chorionic GonadotropinhCGPregnyl

How HCG (Human Chorionic Gonadotropin) Works

HCG binds to the LH/CG receptor on Leydig cells, activating the cAMP/PKA signaling cascade to stimulate steroidogenesis [4]. This maintains intratesticular testosterone production and supports spermatogenesis even when exogenous testosterone suppresses pituitary LH secretion [1]. Its longer half-life (approximately 24-36 hours) compared to native LH allows less frequent dosing [3].

Clinical Evidence

Multiple clinical studies support HCG co-administration during TRT for fertility preservation [3]. A 2005 study by Coviello et al. demonstrated that 250 IU HCG every other day maintained intratesticular testosterone during gonadotropin suppression [1]. Larger observational studies in men's health clinics confirm sustained spermatogenesis in the majority of patients receiving concurrent HCG and TRT [3].

Clinical Uses

  • Fertility preservation during testosterone replacement therapy
  • Hypogonadism support and endogenous testosterone stimulation
  • Post-cycle therapy (PCT) to restore hypothalamic-pituitary-gonadal axis
  • Weight loss protocols (as adjunct to caloric restriction)
  • Cryptorchidism treatment in pediatric patients (FDA-approved indication)

Patient Selection and Screening

Ideal candidates include men on TRT who desire fertility preservation, patients with testicular atrophy symptoms, and those undergoing post-cycle therapy [3]. HCG is contraindicated in patients with hormone-sensitive malignancies or a history of thromboembolism [4]. Prior pituitary imaging is recommended in younger hypogonadal men to rule out structural pathology.

Dosing and Administration

For fertility preservation during TRT, initiate at 500 IU subcutaneously three times weekly and titrate based on semen analysis and estradiol response [1]. If estradiol rises excessively, reduce to 500 IU twice weekly or add an aromatase inhibitor [3]. For post-cycle therapy, higher doses (1000-1500 IU three times weekly for 2-4 weeks) may be used to jumpstart Leydig cell function before transitioning to maintenance [3].

Route
Subcutaneous injection, intramuscular injection
Protocol notes
Typically administered via subcutaneous or intramuscular injection at 500-1500 IU 2-3 times per week when used alongside TRT. Weight loss protocols historically used 125-200 IU daily. Dosing varies by clinical indication and patient response.

Safety and Monitoring

Potential side effects

  • Estradiol elevation due to increased aromatization (may require AI co-administration)
  • Injection site reactions (pain, erythema, swelling)
  • Gynecomastia if estradiol is not monitored and managed
  • Headache and irritability (typically dose-dependent)
  • Rare: ovarian hyperstimulation syndrome in female patients

Clinical considerations

  • FDA regulatory changes (2020 Biologics classification) have affected compounding availability; verify current eligibility
  • Previously classified as a drug; reclassified as a biologic under the BPCI Act, restricting 503A compounding
  • Monitor estradiol levels, as HCG can increase aromatization
  • Contraindicated in hormone-sensitive malignancies (prostate cancer, breast cancer)
  • 503B outsourcing facilities may still compound under different regulatory pathway; confirm with pharmacy

Practice Economics

HCG has historically been one of the highest-volume prescriptions in men's health clinics, generating consistent recurring revenue through TRT adjunct protocols [3]. The biologics reclassification disrupted supply chains [2], but 503B availability and potential legislative changes may restore access. Practices should maintain relationships with multiple pharmacy partners and consider gonadorelin as a backup to avoid patient attrition during supply gaps.

FDA Category Status

Reclassified as biologic (March 2020); compounding eligibility restricted. Verify current 503A/503B status with pharmacy partner

FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify current status before prescribing.

Frequently Asked Questions

Can HCG still be legally compounded after the FDA biologics reclassification?

The regulatory environment has been evolving. HCG was reclassified as a biologic in March 2020 under the BPCI Act, which initially restricted 503A pharmacy compounding. However, 503B outsourcing facilities may operate under different rules, and legislative/regulatory updates continue. Practices should verify current compounding eligibility directly with their pharmacy partner and monitor FDA guidance updates.

Why is HCG used alongside TRT and how should it be dosed?

Exogenous testosterone suppresses LH and FSH via negative feedback, causing testicular atrophy and infertility. HCG mimics LH, maintaining Leydig cell stimulation, intratesticular testosterone production, and spermatogenesis. Typical dosing is 500-1500 IU subcutaneously 2-3 times weekly. Monitor total testosterone, estradiol, and semen analysis to titrate dose.

What are the key monitoring parameters for patients on HCG?

Monitor estradiol (HCG increases aromatization and can elevate E2), total and free testosterone, LH/FSH (should be suppressed if on concurrent TRT), hematocrit, and PSA in appropriate patients. Semen analysis should be performed periodically if fertility preservation is the primary indication. Adjust dose based on estradiol response.

References

  1. Coviello et al. - HCG maintains intratesticular testosterone during gonadotropin suppression (2005)
  2. FDA Biologics Price Competition and Innovation Act (BPCI) - HCG reclassification
  3. Lee & Ramasamy - HCG in male hypogonadism and fertility preservation (2018)
  4. Pregnyl (choriogonadotropin alfa) FDA prescribing information

Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable regulations. Always verify FDA category status and compounding eligibility before prescribing.

Launch a Peptide Program With Karpa

Karpa handles intake, licensed prescribing, and direct-to-patient pharmacy fulfillment across all 50 states. No medical license required.

Explore peptide programs